#184: MS treatment across the disease course – treat early, think long-term, don’t give up too soon with Prof. Klaus Schmierer
How early should MS treatment start – and is there ever a point when treatment becomes too late? Prof. Klaus Schmierer discusses early high-efficacy therapy, immune reconstitution, advanced MS and why meaningful function may still be worth protecting throughout the disease course.
#164: EMSP 2026. Progress, Hope and Real Challenges in Multiple Sclerosis
EMSP 2026 in Berlin highlighted how much is evolving in multiple sclerosis – from new diagnostic criteria and emerging therapies to long-overdue topics like fatigue and PIRA. At the same time, access to care across Europe remains a major challenge. In this article, I share my personal insights and key takeaways from the conference.
#154: How Pharmacovigilance Keeps MS Therapies Safe: From Drug Development to Real-World Monitoring (with Dr. Nora Möhn)
Multiple sclerosis treatments have advanced fast—but safety monitoring matters more than ever. In this interview, Dr. Nora Möhn explains pharmacovigilance step by step: from clinical trial phases and approval to post-marketing surveillance and reporting systems (EU/US/UK/Canada). You’ll learn how neurologists weigh benefits and risks, and how you can discuss side effects confidently.
